Literature DB >> 30149286

Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay.

Wil F Kopatz1, Herm Jan M Brinkman2, Joost C M Meijers3.   

Abstract

Calibrated automated thrombography (CAT) is useful in monitoring the anticoagulant status of patients treated with direct oral anticoagulants (DOACs). This as well as other applications of the CAT are hampered by the wide inter-individual variation, making the diagnosis of the anticoagulant status of a patient on DOAC difficult when using normal pooled plasma as a reference. With dabigatran, the CAT is further hampered, as this direct thrombin inhibitor also inhibits the calibrator that is used in CAT. In this study we examined the added value of the universal DOAC adsorbent DOAC Stop in CAT. For this, we used normal pooled plasma spiked with apixaban, dabigatran, edoxaban or rivaroxaban, and performed CAT with 5 pM tissue factor. DOAC Stop effectively removed DOACs from plasma, leaving the DOAC Stop-treated plasma slightly more procoagulant compared to sham treated, non-anticoagulated plasma. Examining levels of natural coagulation inhibitors revealed a slight reduction in tissue factor pathway inhibitor upon DOAC Stop treatment. When DOAC Stop-treated plasma was used in the calibrator wells, normal unaffected calibration curves were observed, even when dabigatran was present. In conclusion, DOAC Stop can be used to abolish dabigatran influences of anticoagulated plasma when used in the calibrator wells. Also, the anticoagulant status of a DOAC treated patient can be diagnosed simply by comparing untreated plasma with the same plasma sample treated with DOAC Stop. Using this approach, a minor DOAC-independent increase in CAT response in the DOAC Stop-treated sample should be taken into account.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apixaban; DOAC adsorbent; Dabigatran; Direct oral anticoagulants; Edoxaban; Rivaroxaban; Thrombin generation assay

Mesh:

Substances:

Year:  2018        PMID: 30149286     DOI: 10.1016/j.thromres.2018.08.014

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Direct oral anticoagulant (DOAC) interference in hemostasis assays.

Authors:  Karen A Moser; Kristi J Smock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Thrombophilia testing in the era of direct oral anticoagulants.

Authors:  Jennifer Darlow; Holly Mould
Journal:  Clin Med (Lond)       Date:  2021-09-07       Impact factor: 5.410

3.  The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?

Authors:  Pieter M M De Kesel; Katrien M J Devreese
Journal:  Res Pract Thromb Haemost       Date:  2019-12-10

4.  Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing - Evaluation on spiked and patient samples.

Authors:  Eleni A Linskens; Pieter De Kesel; Katrien M J Devreese
Journal:  Res Pract Thromb Haemost       Date:  2022-03-21

Review 5.  Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants.

Authors:  Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Res Pract Thromb Haemost       Date:  2022-03-15

6.  Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop.

Authors:  Viktor Taune; Mika Skeppholm; Anna Ågren; Agneta Wikman; Andreas Hillarp; Håkan Wallén
Journal:  TH Open       Date:  2022-08-29

7.  Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.

Authors:  L Slavik; J Jacova; D Friedecky; J Ulehlova; Z Tauber; J Prochazkova; A Hlusi; M Palova
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

8.  Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.

Authors:  Roisin Bavalia; Rahat Abdoellakhan; Herm Jan M Brinkman; Marjolein P A Brekelmans; Eva N Hamulyák; Marleen Zuurveld; Barbara A Hutten; Peter E Westerweel; Renske H Olie; Hugo Ten Cate; Marieke Kruip; Saskia Middeldorp; Karina Meijer; Michiel Coppens
Journal:  Res Pract Thromb Haemost       Date:  2020-04-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.